Skip to main content
SpringerLink
Log in

Behandlungsansätze bei trockener AMD

  • Chapter
Altersabhängige Makuladegeneration

  • 1245 Accesses

Zusammenfassung

Die altersabhängige Makuladegeneration (AMD) ist in den Industriestaaten der Hauptgrund irreversibler Erblindung bei Menschen über 60 Jahren [1]. Schätzungsweise etwa 30% der Erwachsenen über 75 Jahren weisen Zeichen einer AMD auf, von denen etwa 10% ein fortgeschrittenes oder spätes Stadium der Erkrankung zeigen [2]. Die große Mehrheit der AMD-Patienten haben die nicht-exsudative oder trockene Form der Erkrankung, charakterisiert durch eine Konstellation bestimmter klinischer Zeichen, einschließlich Drusen, Pigmentanomalien (fokale Hyperoder Hypopigmentierungen des retinalen Pigmentepithels (RPE)) und geographischer Atrophie (GA) der Makula. Wie in der Age-Related Eye Disease Studie (AREDS) definiert, kann der Schweregrad der AMD in drei Kategorien eingeteilt werden: früh, intermediär und fortgeschritten.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 139.00
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
Hardcover Book
USD 179.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

Literatur

  1. Klein R, Klein BE, Linton KL (1992) Prevalence of age-related maculopathy. The Beaver Dam Eye Study. Ophthalmology 99(6):933-43

    PubMed  CAS  Google Scholar 

  2. Friedman DS, O’Colmain BJ, Munoz B, et al. (2004) Prevalence of age-related macular degeneration in the United States. Arch Ophthalmol 122(4):564-72

    Article  PubMed  Google Scholar 

  3. Ferris FL, Davis MD, Clemons TE, et al. (2005) A simplified severity scale for age-related macular degeneration: AREDS Report No. 18. Arch Ophthalmol 123(11):1570-4

    Article  PubMed  Google Scholar 

  4. AREDS (2001) A randomized, placebo-controlled, clinical trial of high-dose supplementation with vitamins C and E, beta carotene, and zinc for age-related macular degeneration and vision loss: AREDS report no. 8. Arch Ophthalmol 119(10):1417-36

    Google Scholar 

  5. Evans J (2008) Antioxidant supplements to prevent or slow down the progression of AMD: a systematic review and meta-analysis. Eye (Lond) 22(6):751-60

    CAS  Google Scholar 

  6. Thornton J, Edwards R, Mitchell P, et al. (2005) Smoking and agerelated macular degeneration: a review of association. Eye (Lond) 19(9):935-44

    CAS  Google Scholar 

  7. Seddon JM, Cote J, Rosner B (2003) Progression of age-related macular degeneration: association with dietary fat, transunsaturated fat, nuts, and fish intake. Arch Ophthalmol 121(12):1728-37

    Article  PubMed  Google Scholar 

  8. Ding X, Patel M, Chan CC (2009) Molecular pathology of agerelated macular degeneration. Prog Retin Eye Res 28(1):1-18

    Article  PubMed  CAS  Google Scholar 

  9. Kaidzu S, Tanito M, Ohira A, et al. (2008) Immunohistochemical analysis of aldehyde-modified proteins in drusen in cynomolgus monkeys (Macaca fascicularis). Exp Eye Res 86(5):856-9

    Article  PubMed  CAS  Google Scholar 

  10. Parodi MB, Virgili G, Evans JR (2009) Laser treatment of drusen to prevent progression to advanced age-related macular degeneration. Cochrane Database Syst Rev (3):CD006537

    PubMed  Google Scholar 

  11. Csaky KG, Richman EA, Ferris FL, 3rd. (2008) Report from the NEI/FDA Ophthalmic Clinical Trial Design and Endpoints Symposium. Invest Ophthalmol Vis Sci 49(2):479-89

    Article  PubMed  Google Scholar 

  12. Ralston Jr PG, Sloan D, Waters-Honcu D, et al. (2010) A Pilot, Open-Label Study of the Safety of MC-1101 in Both Normal Volunteers and Patients With Early Nonexudative Age-Related Macular Degeneration. Invest Ophthalmol Vis Sci 51:E-Abstract 913

    Google Scholar 

  13. Tao W, Wen R, Goddard MB, et al. (2002) Encapsulated cell-based delivery of CNTF reduces photoreceptor degeneration in animal models of retinitis pigmentosa. Invest Ophthalmol Vis Sci 43(10):3292-8

    PubMed  Google Scholar 

  14. Beltran WA, Zhang Q, Kijas JW, et al. (2003) Cloning, mapping, and retinal expression of the canine ciliary neurotrophic factor receptor alpha (CNTFRalpha). Invest Ophthalmol Vis Sci 44(8):3642-9

    Article  PubMed  Google Scholar 

  15. Emerich DF, Thanos CG. (2008) NT-501: an ophthalmic implant of polymer-encapsulated ciliary neurotrophic factor-producing cells. Curr Opin Mol Ther 10(5):506-15

    PubMed  CAS  Google Scholar 

  16. Williams GA, Tao W (2009) A Phase II Study of Encapsulated CNTF Secreting Cell Implant (NT-501) in Patients With Visual Acuity Impairment Associated With Atrophic Macular Degeneration. Invest Ophthalmol Vis Sci 50:E-Abstract 5003

    Article  Google Scholar 

  17. Mata NL, Vogel R (2010) Pharmacologic treatment of atrophic age-related macular degeneration. Curr Opin Ophthalmol 21(3):190-6

    Article  PubMed  Google Scholar 

  18. Saylor M, McLoon LK, Harrison AR, et al. (2009) Experimental and clinical evidence for brimonidine as an optic nerve and retinal neuroprotective agent: an evidence-based review. Arch Ophthalmol 127(4):402-6

    Article  PubMed  CAS  Google Scholar 

  19. Schmitz-Valckenberg S, Holz FG, Bird AC, et al. (2008) Fundus autofluorescence imaging: review and perspectives. Retina 28(3):385-409

    Article  PubMed  Google Scholar 

  20. Radu RA, Han Y, Bui TV, et al. (2005) Reductions in serum vitamin A arrest accumulation of toxic retinal fluorophores: a potential therapy for treatment of lipofuscin-based retinal diseases. Invest Ophthalmol Vis Sci 46(12):4393-401

    Article  PubMed  Google Scholar 

  21. Kubota R, Birch D, David R (2009) Phase 1, Dose-Escalating Study of the Safety, Tolerability, and Pharmacokinetics of ACU-4429 in Healthy Volunteers. Invest Ophthalmol Vis Sci 50:E-Abstract 5009

    Article  Google Scholar 

  22. Johnson LV, Leitner WP, Rivest AJ, et al. (2002) The Alzheimer’s A beta -peptide is deposited at sites of complement activation in pathologic deposits associated with aging and age-related macular degeneration. Proc Natl Acad Sci U S A 99(18):11830-5

    Article  PubMed  CAS  Google Scholar 

  23. Ding JD, Lin J, Mace BE, et al. (2008) Targeting age-related macular degeneration with Alzheimer’s disease based immunotherapies: anti-amyloid-beta antibody attenuates pathologies in an age-related macular degeneration mouse model. Vision Res 48(3):339-45

    Article  PubMed  CAS  Google Scholar 

  24. Beatty S, Koh H, Phil M, et al. (2000) The role of oxidative stress in the pathogenesis of age-related macular degeneration. Surv Ophthalmol 45(2):115-34

    Article  PubMed  CAS  Google Scholar 

  25. AREDS (2000) Risk factors associated with age-related macular degeneration. A case-control study in the age-related eye disease study: Age-Related Eye Disease Study Report Number 3. Ophthalmology 107(12):2224-32

    Article  Google Scholar 

  26. Tanito M, Li F, Elliott MH, et al. (2007) Protective effect of TEMPOL derivatives against light-induced retinal damage in rats. Invest Ophthalmol Vis Sci 48(4):1900-5

    Article  PubMed  Google Scholar 

  27. Sternberg P, Rosenfeld PJ, Slakter JS, et al. (2010) Topical OT-551 for Treating Geographic Atrophy: Phase II Results. Invest Ophthalmol Vis Sci 51:E-Abstract 6416

    Google Scholar 

  28. Wong WT, Kam W, Cunningham D, et al. (2010) Topical Administration of Anti-Oxidant, OT-551 for the Treatment of Geographic Atrophy: Results of a Phase I/II Clinical Trial. Invest Ophthalmol Vis Sci 51:E-Abstract 6418

    Google Scholar 

  29. Gehrs KM, Jackson JR, Brown EN, et al. (2010) Complement, agerelated macular degeneration and a vision of the future. Arch Ophthalmol 128(3):349-58

    Article  PubMed  CAS  Google Scholar 

  30. Anderson DH, Radeke MJ, Gallo NB, et al. (2010) The pivotal role of the complement system in aging and age-related macular degeneration: hypothesis re-visited. Prog Retin Eye Res 29(2):95-112

    Article  PubMed  CAS  Google Scholar 

  31. Skeie JM, Fingert J, Russell S, et al. (2010) Complement Component C5a Activates Icam-1 Expression on Human Choroidal Endothelial Cells. Invest Ophthalmol Vis Sci

    Google Scholar 

  32. Patel M, Chan CC (2008) Immunopathological aspects of age-related macular degeneration. Semin Immunopathol 30(2):97-110

    Article  PubMed  Google Scholar 

  33. Klein ML, Ferris FL, 3rd, Francis PJ, et al. (2010) Progression of Geographic Atrophy and Genotype in Age-Related Macular Degeneration. Ophthalmology

    Google Scholar 

  34. Scholl HP, Fleckenstein M, Fritsche LG, et al. (2009) CFH, C3 and ARMS2 are significant risk loci for susceptibility but not for disease progression of geographic atrophy due to AMD. PLoS One 4(10):e7418

    Article  PubMed  Google Scholar 

  35. Nozaki M, Raisler BJ, Sakurai E, et al. (2006) Drusen complement components C3a and C5a promote choroidal neovascularization. Proc Natl Acad Sci U S A 103(7):2328-33

    Article  PubMed  CAS  Google Scholar 

  36. Holers EA (2009) TT30, a Novel Human Protein Therapeutic, Selectively Modulates the Complement Alternative Pathway by Targeted Supplementation of Local Factor H Activity. 51st Annual Meeting of the American Society of Hematology New Orleans, LA

    Google Scholar 

  37. Risitano EA (2009) TT30, A Novel Regulator of the Complement Alternative Pathway (CAP), Inhibits Hemolysis of Paroxysmal Nocturnal Hemoglobinuria (PNH) Erythrocytes and Prevents Upstream C3 Binding On Their Surface in An In Vitro Model. 51st Annual Meeting of the American Society of Hematology New Orleans, LA 2009

    Google Scholar 

  38. Landa G, Butovsky O, Shoshani J, et al. (2008) Weekly vaccination with Copaxone (glatiramer acetate) as a potential therapy for dry age-related macular degeneration. Curr Eye Res 33(11):1011-3

    Article  PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Bascom Palmer Eye Institute, 900 NW 17th St., 33136, Miami, FL, USA

    Dr. Zohar Yehoshua & Prof. Dr. Philip J. Rosenfeld

Authors
  1. Dr. Zohar Yehoshua
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Prof. Dr. Philip J. Rosenfeld
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

Copyright information

© 2011 Springer-Verlag Berlin Heidelberg

About this chapter

Cite this chapter

Yehoshua, Z., Rosenfeld, P. (2011). Behandlungsansätze bei trockener AMD. In: Altersabhängige Makuladegeneration. Springer, Berlin, Heidelberg. https://doi.org/10.1007/978-3-642-20870-6_17

Download citation

  • DOI: https://doi.org/10.1007/978-3-642-20870-6_17

  • Publisher Name: Springer, Berlin, Heidelberg

  • Print ISBN: 978-3-642-20869-0

  • Online ISBN: 978-3-642-20870-6

  • eBook Packages: Medicine (German Language)

Publish with us

Policies and ethics

Search

Navigation